- Aytu BioScience (NASDAQ:AYTU): FQ2 GAAP EPS of -$0.72 misses by $0.28.
- Revenue of $15.15M (+376.4% Y/Y) beats by $2.9M.
- Ended the quarter with $62.3M in cash, equivalents and restricted cash.
- Announced definitive merger agreement with Neos Therapeutics, creating a combined $100M revenue specialty pharmaceutical company.
- Shares -5.26%.
- Press Release
Aytu BioScience EPS misses by $0.28, beats on revenue
Recommended For You
About AYTU Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
AYTU | - | - |
Aytu BioPharma, Inc. |